Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0376358 (prostate cancer)
 59,338 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Functional disorders of the gastrointestinal tract comprise a common but ill-defined group of diseases; they primarily afflict women. Although predominantly involving nerve and muscle, the cellular and molecular bases of the pathogenesis of these functional disorders are unknown. Clinical studies indicate that some result from neural dysfunction within the enteric nervous system, others may be due to muscular problems, and the causes of still others remain unknown. Laboratory studies have shown that ovarian products such as progesterone, luteinizing hormone, human chorionic gonadotropin, and relaxin (but not estrogen), are neural antagonists of gastrointestinal motility. The production and secretion of these ovarian substances are controlled by gonadotropin-releasing hormone (GnRH) released from the hypothalamus; they probably act on gamma-aminobutyric acid receptors and alter chloride influx into the cell. GnRH analogs are effective drugs that downmodulate the hypothalamic-pituitary-gonadal axis and inhibit the secretion of gonadal products involved in such hormone-dependent diseases as endometriosis and prostate cancer. Acting on the GnRH receptors (seven transmembrane domain receptors) on myenteric neurons, GnRH analogs are also effective neural modulators in such disorders as functional bowel disease. These analogs are a promising new group of compounds that may be used to treat difficult gastrointestinal problems.
 ...
PMID:Relationship of reproductive hormones and neuromuscular disease of the gastrointestinal tract. 954 31

Leuprolide acetate is a synthetic nonapeptide that is a potent gonadotropin-releasing hormone receptor (GnRHR) agonist used for diverse clinical applications, including the treatment of prostate cancer, endometriosis, uterine fibroids, central precocious puberty and in vitro fertilization techniques. As its basic mechanism of action, leuprolide acetate suppresses gonadotrope secretion of luteinizing hormone and follicle-stimulating hormone that subsequently suppresses gonadal sex steroid production. In addition, leuprolide acetate is presently being tested for the treatment of Alzheimer's disease, polycystic ovary syndrome, functional bowel disease, short stature, premenstrual syndrome and even as an alternative for contraception. Mounting evidence suggests that GnRH agonist suppression of serum gonadotropins may also be important in many of the clinical applications described above. Moreover, the presence of GnRHR in a multitude of non-reproductive tissues including the recent discovery of GnRHR expression in the hippocampi and cortex of the human brain indicates that GnRH analogs such as leuprolide acetate may also act directly via tissue GnRHRs to modulate (brain) function. Thus, the molecular mechanisms underlying the therapeutic effect of GnRH analogs in the treatment of these diseases may be more complex than originally thought. These observations also suggest that the potential uses of GnRH analogs in the modulation of GnRH signaling and treatment of disease has yet to be fully realized.
 ...
PMID:Leuprolide acetate: a drug of diverse clinical applications. 1797 Jun 43

Accurate interpretation of posttherapeutic images obtained in radiation oncology patients requires familiarity with modern radiation therapy techniques and their expected effects on normal tissues. Three-dimensional conformal external-beam radiation therapy techniques (eg, intensity-modulated radiation therapy, stereotactic body radiation therapy), although they are designed to reduce the amount of normal tissue exposed to high-dose radiation, inevitably increase the amount of normal tissue that is exposed to low-dose radiation, with the potential for resultant changes that may evolve over time. Currently available internal radiation therapy techniques (eg, arterial radioembolization for hepatic malignancies, brachytherapy for prostate cancer and gynecologic cancers) also carry risks of possible injury to adjacent nontargeted tissues. The sensitivity of tissues to radiation exposure varies according to the tissue type but is generally proportional to the rate of cellular division, with rapidly regenerating tissues such as intestinal mucosa being the most radiosensitive. The characteristic response to radiation-induced injury likewise varies according to tissue type, with atrophy predominating in epithelial tissue whereas fibrosis predominates in stromal tissue. Moreover, changes in irradiated tissues evolve over time: In the liver, decreased attenuation at computed tomography and increased signal intensity at T2-weighted magnetic resonance imaging reflect hyperemia and edema in the early posttherapeutic period; later, veno-occlusive changes alter the hepatic enhancement pattern; and finally, fibrosis develops in some patients. In the small bowel, wall thickening and mucosal hyperenhancement predominate initially, whereas luminal narrowing is the most prominent feature of chronic enteropathy. Correlation of posttherapeutic images with images used for treatment planning may be helpful when interpreting complex cases.
 ...
PMID:Imaging effects of radiation therapy in the abdomen and pelvis: evaluating "innocent bystander" tissues. 2347 16